Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,141.05
    +62.19 (+0.77%)
     
  • Bitcoin USD

    64,019.53
    +436.96 (+0.69%)
     
  • CMC Crypto 200

    1,342.95
    -53.59 (-3.73%)
     
  • S&P 500

    5,101.56
    +53.14 (+1.05%)
     
  • Dow

    38,245.27
    +159.47 (+0.42%)
     
  • Nasdaq

    15,913.31
    +301.55 (+1.93%)
     
  • Gold

    2,349.90
    +7.40 (+0.32%)
     
  • Crude Oil

    83.64
    +0.07 (+0.08%)
     
  • 10-Yr Bond

    4.6510
    -0.0550 (-1.17%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years

Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth. Why has Gilead Sciences stock struggled? The simple reason for Gilead's woes is that the business has had trouble generating growth.